New therapeutic strategies for the treatment of acute lymphoblastic leukaemia (Q36724661)

15 August 2017

1 reference

title

New therapeutic strategies for the treatment of acute lymphoblastic leukaemia (English)

1 reference

15 August 2017

1 reference

1

Ching-Hon Pui

1 reference

15 August 2017

Sima Jeha

2

1 reference

15 August 2017

publication date

1 February 2007

1 reference

Nature Reviews Drug Discovery

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

149-165

1 reference

Treatment of acute lymphoblastic leukemia

15 August 2017

cites work

1 reference

Long-term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk-based Health Care for Survivors

31 March 2020

1 reference

Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia

31 March 2020

1 reference

Acute lymphoblastic leukemia

31 March 2020

1 reference

Molecular genetics of acute lymphoblastic leukemia

31 March 2020

1 reference

Thymic generation and regeneration

31 March 2020

1 reference

Acute lymphoblastic leukemia

31 March 2020

1 reference

Childhood acute lymphoblastic leukaemia--current status and future perspectives

31 March 2020

1 reference

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia

31 March 2020

1 reference

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling

31 March 2020

1 reference

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia

31 March 2020

1 reference

Global approach to the diagnosis of leukemia using gene expression profiling

31 March 2020

1 reference

MicroRNA expression profiles classify human cancers

31 March 2020

1 reference

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia

31 March 2020

1 reference

The RB and p53 pathways in cancer

31 March 2020

1 reference

Tumor suppressor genes in normal and malignant hematopoiesis

31 March 2020

1 reference

Live or let die: the cell's response to p53

31 March 2020

1 reference

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

31 March 2020

1 reference

Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia

31 March 2020

1 reference

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

31 March 2020

1 reference

Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis

31 March 2020

1 reference

Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

31 March 2020

1 reference

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia

31 March 2020

1 reference

Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL).

31 March 2020

1 reference

Phase I study of liposomal vincristine

31 March 2020

1 reference

Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia

31 March 2020

1 reference

From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates

31 March 2020

1 reference

Trimetrexate in relapsed T-cell lymphoma with skin involvement.

31 March 2020

1 reference

Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.

31 March 2020

1 reference

The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma

31 March 2020

1 reference

Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy

31 March 2020

1 reference

A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia

31 March 2020

1 reference

2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia.

31 March 2020

1 reference

Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study

31 March 2020

1 reference

Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity

31 March 2020

1 reference

Synthesis and biological activity of 2'-fluoro-2-halo derivatives of 9-.beta.-D-arabinofuranosyladenine

31 March 2020

1 reference

2-fluoro-ATP: a toxic metabolite of 9-beta-D-arabinosyl-2-fluoroadenine

31 March 2020

1 reference

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

31 March 2020

1 reference

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

31 March 2020

1 reference

Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia

31 March 2020

1 reference

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia

31 March 2020

1 reference

Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity

31 March 2020

1 reference

SYNTHESIS OF 9-BETA-D-ARABINOFURANOSYLGUANINE.

31 March 2020

1 reference

Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies

31 March 2020

1 reference

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group

31 March 2020

1 reference

One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase

31 March 2020

1 reference

Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent

31 March 2020

1 reference

A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)

31 March 2020

1 reference

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

31 March 2020

1 reference

An open study of B lymphocyte depletion in systemic lupus erythematosus

31 March 2020

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

31 March 2020

1 reference

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

31 March 2020

1 reference

Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia

31 March 2020

1 reference

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies

31 March 2020

1 reference

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

31 March 2020

1 reference

Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma

31 March 2020

1 reference

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

31 March 2020

1 reference

Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab

31 March 2020

1 reference

Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.

31 March 2020

1 reference

A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma

31 March 2020

1 reference

Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation

31 March 2020

1 reference

Remission of adult acute lymphocytic leukaemia with alemtuzumab

31 March 2020

1 reference

Activity of alemtuzumab in patients with CD52-positive acute leukemia

31 March 2020

1 reference

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

31 March 2020

1 reference

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.

31 March 2020

1 reference

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

31 March 2020

1 reference

Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.

31 March 2020

1 reference

Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin

31 March 2020

1 reference

Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia

31 March 2020

1 reference

Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation

31 March 2020

1 reference

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

31 March 2020

1 reference

Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia

31 March 2020

1 reference

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

31 March 2020

1 reference

Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study

31 March 2020

1 reference

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

31 March 2020

1 reference

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia

31 March 2020

1 reference

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

31 March 2020

1 reference

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

31 March 2020

1 reference

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

31 March 2020

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

31 March 2020

1 reference

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

31 March 2020

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

31 March 2020

1 reference

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

31 March 2020

1 reference

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

31 March 2020

1 reference

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

31 March 2020

1 reference

FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.

31 March 2020

1 reference

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

31 March 2020

1 reference

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

31 March 2020

1 reference

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification

31 March 2020

1 reference

FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia

31 March 2020

1 reference

FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression

31 March 2020

1 reference

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects

31 March 2020

1 reference

IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples

31 March 2020

1 reference

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

31 March 2020

1 reference

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

31 March 2020

1 reference

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

31 March 2020

1 reference

Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status

31 March 2020

1 reference

Hypermethylation of the 5' CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia

31 March 2020

1 reference

Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia

31 March 2020

1 reference

5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy

31 March 2020

1 reference

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

31 March 2020

1 reference

Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.

31 March 2020

1 reference

Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia

31 March 2020

1 reference

Phase I study of temozolomide in relapsed/refractory acute leukemia

31 March 2020

1 reference

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

31 March 2020

1 reference

Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.

31 March 2020

1 reference

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

31 March 2020

1 reference

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

31 March 2020

1 reference

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

31 March 2020

1 reference

The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines

31 March 2020

1 reference

Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells

31 March 2020

1 reference

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL

31 March 2020

1 reference

Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles

31 March 2020

1 reference

Anthracyclines, proteasome activity and multi-drug-resistance

31 March 2020

1 reference

Phase I study of bortezomib in refractory or relapsed acute leukemias

31 March 2020

1 reference

Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.

31 March 2020

1 reference

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

31 March 2020

1 reference

Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation

31 March 2020

1 reference

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias

31 March 2020

1 reference

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

31 March 2020

1 reference

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

31 March 2020

1 reference

ZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic Leukemia

31 March 2020

1 reference

Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, a

31 March 2020

1 reference

Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.

31 March 2020

1 reference

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

31 March 2020

1 reference

Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.

31 March 2020

1 reference

Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.

31 March 2020

1 reference

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine

31 March 2020

1 reference

Cell-cycle checkpoints and cancer

31 March 2020

1 reference

Intrinsic tumour suppression

31 March 2020

1 reference

31 March 2020

Targeted cancer therapy

1 reference

RNA interference and potential therapeutic applications of short interfering RNAs

31 March 2020

1 reference

Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts

31 March 2020

1 reference

Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.

31 March 2020

1 reference

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

31 March 2020

1 reference

Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?

31 March 2020

1 reference

Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.

31 March 2020

1 reference

Pharmacogenetics of outcome in children with acute lymphoblastic leukemia

31 March 2020

1 reference

Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes

31 March 2020

1 reference

Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD2240

1 reference

Dimensions Publication ID

15 August 2017

1026177261

0 references

1 reference